Manalapan, NJ

Garden State Heart Care

Cardiovascular Diseases

Type 2 Diabetes Mellitus

Embolism

Heart Failure

Diabetes Mellitus

Atrial Fibrillation

Atherosclerosis

Stroke

Apixaban

Finerenone

sodium

Bayer

Duke University

Novartis

condition

allSponsorName

gender

Male

Female

overallStatus

Recruiting

Not yet recruiting

Active, not recruiting

Enrolling by invitation

Completed

Terminated

Withdrawn

Suspended

Unknown

type

Interventional

Observational

Expanded Access

phase

Early Phase 1

Phase 1

Phase 2

Phase 3

Phase 4

Not Applicable

funderTypes

Industry

Other U.S. Federal agency

All others

ageGroup

Child (birth-17)

Adult (18-64)

Older Adult (65+)

Study CKJX839B12302 is a pivotal Phase III trial to evaluate the benefits of inclisiran on major adverse cardiovascular (MACE) events in participants with established cardiovascular disease (CVD).

Study of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease

Garden State Heart Care | Manalapan, NJ

Site insights

Work at this site?

Active trials

Study of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease (VICTORION-2P)

Trial sponsors